Moffitt Cancer Center 20th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2025

Moffitt Cancer Center 20th Annual Clinical Breakthroughs and Challenges in Hematologic Malignancies 2025

This annual conference is a premier forum designed to present the most recent diagnostic and therapeutic advances in hematologic malignancies. Hosted by the Moffitt Cancer Center, one of the nation’s leading cancer research institutes, the 2025 event continued its tradition of offering “breakthrough” updates that bridge the gap between research and bedside practice. The program is structured around interactive debates and “State of the Art” lectures, providing a comprehensive review of lymphoid and myeloid malignancies, plasma cell dyscrasias, and the evolving landscape of cellular immunotherapies.

+ What You Will Learn

Attendees were able to:

• Evaluate the latest clinical data regarding CAR T-cell therapy and bispecific antibodies, specifically their sequencing and toxicity management in lymphoma and myeloma.

• Discuss the role of Measurable Residual Disease (MRD) testing in guiding treatment decisions for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

• Identify new therapeutic targets and agents for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma.

• Analyze the “Hot Topics” in blood cancers, including the management of clonal hematopoiesis and its risk implications for older adults.

• Debate controversial management strategies, such as the use of hypomethylating agents prior to transplant in high-risk MDS, through interactive pro/con sessions.

• Implement best practices for managing complications of novel immunotherapies, including Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS).

+ Event Details

• Date: January 25, 2025

• Location: Florida (Historically held at venues like The Don CeSar in St. Pete Beach or Disney’s Grand Floridian in Orlando; the 21st Annual is confirmed for St. Pete Beach).

• Organizer: Moffitt Cancer Center

+ Who Should Attend

The conference is tailored for the interdisciplinary hematology-oncology team:

• Hematologists and Medical Oncologists

• Oncology Nurses and Nurse Practitioners

• Physician Assistants

• Pharmacists specializing in oncology/hematology

• Research Scientists and Fellows

+ Why Attend

• Cutting-Edge Science: Moffitt Cancer Center is a leader in cellular therapy (CAR T), and this conference provides direct access to the faculty driving these innovations.

• Debate Format: Unlike standard lecture series, this event features “Interactive Debates” (e.g., Transplant vs. CAR T in Myeloma), which help clinicians understand the nuance behind conflicting guidelines.

• ASH Updates: Held shortly after the American Society of Hematology (ASH) annual meeting, this course serves as a critical “post-ASH” review, distilling thousands of abstracts into actionable clinical pearls for the coming year.

• Management of First MM Relapse Debate – Cilta-Cel for All – No
• Management of First MM Relapse Debate – Cilta-Cel for All – Yes
• State-of-the-Art – Understanding Precursor States – CHIP and CCUS
• 2025 Updates on Treating Anemia in LR-MDS
• Debate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS & AML – Yes
• Debate – Should MRD Status Be Used to Alter Treatment Decisions in High-Risk MDS & AML – No
• Beyond CAR-T – Management of Post-BCMA CAR-T Relapse in RRMM
• How I Treat High-Risk Multiple Myeloma – Interactive Case Discussion
• AQUILA Trial – Daratumumab vs. Active Monitoring in SMM – Perspectives for Practice
• Summary of Data for Transplant-Ineligible NDMM – Proposed SoC Approach
• LR-MDS Updates + Panel Discussion – Focus on Ph3 IMerge Trial
• Revmibeni for KMT2Ar RR Acute Leukemia – AUGMENT-101 Trial – Impact on Treatment Landscape
• Clinical Application of Practice-Changing SWOG S1826 Trial – Nivo+AVD vs. BV+AVD in 1L Advanced Stage cHL
• Golcadomide + R-CHOP in High-Risk, Untreated Aggressive B-cell Lymphoma – Panel Discussion on Future of 1L Therapy in DLBCL